uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Prediction of Mild Cognitive Impairment that Evolves into Alzheimer's Disease Dementia within Two Years using a Gene Expression Signature in Blood: A Pilot Study
Show others and affiliations
2013 (English)In: Journal of Alzheimer's Disease, ISSN 1387-2877, E-ISSN 1875-8908, Vol. 35, no 3, 611-621 p.Article in journal (Refereed) Published
Abstract [en]

Background: The focus on Alzheimer's disease (AD) is shifting from dementia to the prodromal stage of the disorder, to a large extent due to increasing efforts in trying to develop disease modifying treatment for the disorder. For development of disease-modifying drugs, a reliable and accurate test for identification of mild cognitive impairment (MCI) due to AD is essential. Objective: In the present study, MCI progressing to AD will be predicted using blood-based gene expression. Material and Methods: Gene expression analysis using qPCR was performed on blood RNA from a cohort of patients with amnestic MCI (aMCI; n = 66). Within the aMCI cohort, patients progressing to AD within 1 to 2 years were grouped as MCI converters (n = 34) and the patients remaining at the MCI stage after 2 years were grouped as stable MCI (n = 32). AD and control populations were also included in the study. Results: Multivariate statistical method partial least square regression was used to develop predictive models which later were tested using leave-one-out cross validation. Gene expression signatures that identified aMCI subjects that progressed to AD within 2 years with a prediction accuracy of 74%-77% were identified for the complete dataset and subsets thereof. Conclusion: The present pilot study demonstrates for the first time that MCI that evolves into AD dementia within 2 years may be predicted by analyzing gene expression in blood. Further studies will be needed to validate this gene signature as a potential test for AD in the predementia stage.

Place, publisher, year, edition, pages
2013. Vol. 35, no 3, 611-621 p.
Keyword [en]
Alzheimer's disease, biomarkers, diagnostic tests, gene expression signatures, mild cognitive impairment
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-201889DOI: 10.3233/JAD-122404ISI: 000318627800017OAI: oai:DiVA.org:uu-201889DiVA: diva2:629681
Available from: 2013-06-17 Created: 2013-06-17 Last updated: 2017-12-06Bibliographically approved

Open Access in DiVA

fulltext(353 kB)468 downloads
File information
File name FULLTEXT01.pdfFile size 353 kBChecksum SHA-512
ccdf08f6b073526906df7bbbf906c33b3486e788e8c2fd223a44a55ac281bc213495c67c4aeddd7ef6b25162eac85c6220dccc7eddaa1917adc383db8090c850
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Authority records BETA

Lannfelt, Lars

Search in DiVA

By author/editor
Lannfelt, Lars
By organisation
Geriatrics
In the same journal
Journal of Alzheimer's Disease
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 468 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 420 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf